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Abstract. Circulating tumour cells (CTCs) are cancer cells of 
epithelial origin that are present in peripheral blood samples. 
ScreenCell detection of CTCs and the association with long 
term survival in non-small cell lung cancer (NSCLC) patients 
was evaluated in the present study. A total of 33 patients 
undergoing surgical resection for NSCLC were recruited. 
Patients were followed up for 5-years post-operatively. 
Pre-operative patient bloods samples were processed using 
ScreenCell. CTCs were detected in 26 (79%) patients. In 
patients who were positive for CTCs, a total of 9 (35%) 
patients succumbed to the disease, whereas in patients 
negative for CTCs, a total of 4 (57%) patients succumbed to 
the disease (P=0.29). No association was identified between 
positive CTCs and poorer survival (Chi-squared 1.47, P=0.23; 
hazard ratio, 0.42; 95% confidence interval: 0.1-1.7). The 
presence of CTCs detected with ScreenCell does not influence 
prognosis in patients with NSCLC that was operated on. The 
high rate of CTC detection is encouraging in supporting this 
technology to aid early lung cancer diagnosis.
Introduction
Lung cancer remains the leading cause of cancer-related 
mortality amongst men and women in the United Kingdom (1). 
The lack of symptoms in the early disease means that three 
quarters of lung cancers are diagnosed at a late stage, often 
disqualifying patients from curative treatment (2). Screening 
with early diagnosis and treatment has been shown to improve 
survival (3).
Metastatic disease is responsible for most cancer deaths and 
for this to occur tumour cells must separate from the primary 
tumour and circulate in the bloodstream to distant sites (4). 
Circulating tumour cells (CTCs) are cancer cells of epithelial 
origin that are present in the peripheral blood samples of 
cancer patients. They form a subpopulation of tumour cells 
which intravasate to allow haematogenous dissemination to 
other areas of the body, contributing to metastatic spread (4). 
Their use includes early detection of cancers, monitoring 
response to treatment and assessing for reoccurrence (5).
Isolation of CTCs has been attempted by using physical 
features such as their larger size and weight, antibody based 
platforms, and microfluidic techniques, where spaces and flows 
are commensurate with a scale of single cells, allowing CTCs 
to be captured (6,7). ScreenCell detection of CTCs relies on 
the size of the CTC and is not antibody dependent, removing 
the antibody-bias we see with some other techniques.
We have investigated the use of ScreenCell in operated 
patients with lung cancer in previous studies (8-12). In this 
study we evaluate the value of CTC detection and association 
with long term survival.
Our main outcome of interest was whether the presence of 
CTCs would impact long term survival. Secondary outcomes 
of interest included whether the presence of CTCs would corre-
late with the stage of the cancer and if there was a difference 
between histological subtype of tumour and the proportion of 
patients with CTCs. In addition to evaluate for any differences 
in the proportion of CTCs in patients undergoing a thoraco-
scopic or open surgical approach.
Patients and methods
A total of 33 patients undergoing surgical treatment with 
curative intent for non-small cell lung cancer (NSCLC) 
were recruited from August, 2012 to June, 2015 at Harefield 
Hospital (Uxbridge, UK). The median age of the patients 
was 66 years (range, 41-87 years) and 15 (45%) patients were 
male. Patients had a confirmed diagnosis of NSCLC either 
pre-operatively or on an intra-operative frozen section. Ethical 
approval was sought prior (ethical approval no. 10/H0504/9), 
with consent obtained pre-operatively. Patients who 
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participated in this research had complete clinical data. The 
signed informed consents were obtained from the patients or 
the guardians. Surgery was performed under the care of four 
thoracic surgeons at a tertiary thoracic centre. Operations were 
performed via a thoracotomy or via video assisted thoracotomy 
surgery (VATS) approach. One case was performed via a 
sternotomy where there were bilateral lung lesions.
Patients were followed-up for a median time period of 
5 years post-operatively. Survival information was obtained by 
contacting the patient's General Practitioner in January, 2018.
The detailed technique of CTC detection using the 
ScreenCell device is described elsewhere (9). Briefly, three 
millilitres of blood was collected from the peripheral vein of 
patients immediately prior to surgery in EDTA tubes. Samples 
were incubated with a lysis and formaldehyde fixation buffer 
provided by ScreenCell. Samples were then filtered through 
the ScreenCell® device as per the manufacturer's protocol.
Post-filtration filters were removed and stained with 
haematoxylin and eosin (H&E) staining. Stained filters were 
then mounted on to slides and viewed by a consultant patholo-
gist to assess for the presence of CTCs. All patient samples 
were processed using the ScreenCell device and scored 
as being either negative or positive for CTCs, based on the 
following characteristics, large epithelioid cells with, nuclear 
enlargement and an increased nuclear to cytoplasmic ratio.
All recruited patients were diagnosed with NSCLC, of 
which 21 (64%) patients were diagnosed with adenocarcinoma 
and 12 (36%) patients with squamous cell carcinoma. The 
median age of the patients was 64 years, with an interquartile 
range (IQR) of 13.7 years. Fifteen (45%) patients were male. 
Fifteen (45%) patients had stage I lung cancer, eleven (33%) 
patients had stage II, 6 (15%) patients had stage III and 1 (3%) 
patient had stage IV disease (T3N2M1a) due to a metastatic 
pleural deposit at the time of surgical resection.
Twenty-eight (85%) patients had a lobectomy, 1 (3%) patient 
required pneumonectomy, and 4 (12%) patients who were not 
fit enough for a lobectomy had a wedge resection. Surgery 
was performed thoracoscopically in 7 (21%) patients and with 
an open approach in 26 (79%) patients (25 thoracotomies, 
1 sternotomy due to bilateral lesions).
Statistical analysis was calculated on GraphPad Prism 
version 5 (GraphPad Software, Inc.), and the survival 
proportion was analysed as a Kaplan-Meier plot. Statistical 
significance was calculated using a Chi-square test, and a 
hazard ratio (HR) was calculated with a 95% confidence 
interval (CI). The analysis between lung cancer stage and 
the proportion of patients with positive CTCs was performed 
using Pearson's correlation. Tumour node metastasis version 7 
was used for staging patients. Analysis between groups was 
performed using a two-sided Student's t-test.
Table I. Median survival depending on histology and CTC status.
 CTC status Median survival (months)
 -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
Histology Total Detected Not detected Total CTCs detected CTCs not detected
Adenocarcinoma 21 (64%) 17 (81%) 4 (19%)  38 38 31
SqCC 12 (36%)   9 (75%) 3 (25%) 53 60 34
Total 33 26 (79%) 7 (21%) 39   47a  34a
aComparison using the Chi‑square test showed no significant difference in median survival between patients with and without CTCs. SqCC, 
squamous cell carcinoma; CTCs, circulating tumour cells.
Figure 1. Kaplan‑Meier plots of survival for patients positive and negative for 
CTCs. There was no relationship between positive CTCs and poorer survival 
(Chi-squared 1.47, P=0.23; hazard ratio 0.42, 95% CI: 0.1-1.7). CTCs, circu-
lating tumour cells; CI, confidence interval.
Figure 2. Pearson correlation of the percentage of patients with positive 
circulating tumours cells and lung cancer stage. Pearson's correlation 
coefficient r=‑0.80, P=0.20. CTCs, circulating tumour cells.
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Results
CTCs were detected in 26 (79%) patients. At the end of our 
follow-up period at a median of 5 years, 20 patients (61%) were 
still alive (Table I). In patients who were positive for CTCs 
9 out of 26 patients (35%) had succumbed to the disease, 
whereas in patients negative for CTCs 4 out of 7 (57%) patients 
had succumbed to the disease (P=0.29). Of the 13 patients 
who succumbed to the disease 9 (69%) had CTCs detected. 
Whereas in the 20 patients who were still alive 17 (85%) had 
detected CTCs.
Overall survival was analysed using a Kaplan Meier plot 
(Fig. 1) of patients positive and negative for CTCs. It showed 
no relationship between positive CTCs being associated with 
poorer survival, Chi-squared 1.47, P=0.23, HR=0.42 (95% CI: 
0.1-1.7). Median survival in patients with CTCs was 46.5 months 
whereas it was only 34.1 months in patients without CTCs.
There was no direct correlation between the stage and 
detection of CTCs (Table II). A Pearson's analysis (Fig. 2) 
between proportion of patients with positive CTCs status 
and lung cancer stage showed negative correlation, Pearson's 
r=-0.80, P=0.20.
Of the 21 patients with adenocarcinoma 17 (81%) patients 
had positive CTCs whereas of the 12 patients with squa-
mous cell carcinoma 9 (75%) patients had positive CTCs 
(P=0.70) (Table I).
A total of 6 of the 7 (86%) patients that had their operation 
performed thoracoscopically were positive for CTCs whereas 
20 of the 26 (77%) patients that had an open operation were 
positive for CTCs (P=0.63; Table III). Survival in the patients 
undergoing a thoracoscopic approach was 51 vs. 38 months in 
the open group (P=0.43).
Survival was better, although not significantly, in women 
positive for CTCs compared with men (58 vs. 38 months, 
Table II. Survival depending on lung cancer stage and CTC status.
 Total CTC status
 -------------------------------------------------------------------- -------------------------------------------------------------------------------
Stage Total (%) Alive Deceased Detected Not detected
1 15 (45.4%)   9 (60%) 6 (40%) 13 (87%) 2 (13%)
2 11 (33.3%)   8 (73%) 3 (27%)   8 (73%) 3 (27%)
3   6 (18.1%)   3 (50%) 3 (50%)   5 (83%) 1 (17%)
4 1 (3.3%) 0 (0%) 1 (100%) 0 (0%)   1 (100%)
Total 33 20 (61%) 13 (39%) 26 (79%) 7 (21%)
There was no direct correlation between the stage and detection of CTCs. A Pearson's analysis between proportion of patients with positive 
CTCs status and lung cancer stage demonstrated a negative correlation, Pearson's r=-0.80, P=0.20. CTC, circulating tumour cells.
Table III. Median survival based on operative approach and CTC status.
 CTC detected CTC not detected
 ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
Surgery Total Total (%) Survival (months) Total (%) Survival (months)
VATS   7   6 (86)a 54b 1 (14) 23b
Open 26 20 (77)a 38b 6 (23) 37b
aNo significant difference was observed in the proportion of patients in the VATS or open group who were positive for CTCs, P=0.63. bSurvival 
in the patients undergoing a thoracoscopic approach was improved but not significantly, P=0.43. CTC, circulating tumour cells. 
Table IV. Median survival based on gender and CTC status.
 CTC detected CTC not detected
 ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
Sex Total Total (%) Survival (months) Total (%) Survival (months)
Female 18 14 (43) 58a   4 (12) 37a
Male 15 12 (36) 38b 3 (9) 21b
aSurvival was improved, although not significantly, in women positive for CTCs compared with men, P=0.43. bIn women negative for CTCs 
survival was longer, compared to men, but this was notindicated to be significant, P=0.61. CTC, circulating tumour cells.
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respectively), P=0.43. In women negative for CTCs survival 
was 37 months compared to 21 months in men negative for 
CTCs (P=0.61; Table IV).
In the subgroup of patients who underwent a wedge 
resection 3 of the 4 patients (75%) were positive for CTCs, 
whereas in the group undergoing lobectomy or pneumonec-
tomy 23 out of 29 patients (79%) were positive for CTCs 
(P=0.85).
Discussion
Previously we demonstrated the ability of ScreenCell in 
detecting CTCs in patients with lung cancer (8). In this 
study we sought to evaluate the impact of positive CTCs on 
long term follow-up. There was no effect of the presence of 
CTCs on median survival, in fact their presence was actually 
surprisingly associated with longer median survival compared 
to those patients negative for CTCs, although not significantly. 
This was also the case when we analysed the results with 
shorter follow up and fewer patients (8).
It is known that different types of lung cancer metastasize 
via difference means and this can reflect their potential to 
spread. Small cell lung cancer and undifferentiated NSCLC 
spread via single cell or small cell cluster movement 
whereas in adenocarcinoma and squamous cell carcinoma 
spread results from movement of large clusters of organised 
cells (13). ScreenCell looks for individual CTCs. Given that 
all patients in our cohort had either adenocarcinoma or squa-
mous cell carcinoma it may be that the presence of isolated 
CTCs is not clinically relevant to the metastatic potential as 
these tumour will not metastasize until organised clusters 
of cells are formed. In our cohort there was no difference 
in the proportion of CTCs between adenocarcinomas and 
squamous cell carcinomas however this likely reflects that 
they both metastasize in a similar way (13). The improved 
prognosis (although not significant) in patients with CTCs 
may reflect the fact that detection of single CTCs primes the 
immune system to respond to organised clusters of cells.
Our data did not show a significant association between 
the proportion of patients with CTCs and lung cancer stage 
(Fig. 2). However it is interesting to note that even in patients 
with stage I lung cancer 87% of patients had CTCs found in 
a sample of peripheral blood. Thus even at this early stage 
lung cancers are producing CTCs which can be detected in a 
peripheral blood sample. This highlights the potential impor-
tance that the detection of CTCs could have as a screening test 
for early stage lung cancer.
There is evidence to support that patients undergoing a 
VATS lobectomy for early stage lung cancer have improved 
survival compared to those patients undergoing an open 
operation. One potential reason for this is that there is reduced 
manipulation of the lung and the tumour with a VATS approach 
compared to open surgery, which reduces the number of CTCs 
shed during surgery (14,15). However we were unable to detect 
any difference in the number of CTCs between VATS and 
open surgery to support this theory although the numbers in 
our VATS group were small.
Limitations of our study included the small sample size of 
33 patients and the heterogeneity of the cohort with patients 
with different lung cancer stage. The study was designed 
as a pilot study to assess whether a link exists between 
ScreenCell detected CTCs and prognosis. Although there was 
heterogeneity in the cohort it was designed to reflect clinical 
practice of patients operated on for lung cancer.
Our result show that the presence of CTCs detected with 
ScreenCell does not have an effect on prognosis in patients 
with operated NSCLC. We believe that this may reflect the fact 
the ScreenCell detects single cells which may not be relevant 
to the metastatic potential of lung adenocarcinoma and squa-
mous cell carcinoma.
There was no relationship between lung cancer stage and 
the proportion of patients with CTCs. It is interesting that even 
in stage I lung cancers more than 80% of patients were found 
to have detectable CTCs which is encouraging in supporting 
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